Purchase this article with an account.
M.A. Martinez–Castellanos, M. Parrochia, H. Quiroz–Mercado, J.L. Guerrero–Naranjo, O. Ustariz, O. Ustariz, M. Abraham, M.L. Hernandez, M.L. Hernandez, G. Alvarez; Safety And Efficacy Of Intravitreal Bevacizumab For Idiopathic Subfoveal Choroidal Neovascularization. Pilot Study . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4282.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the safety an efficacy of intravitreal bevacizumab in the treatment of idiopathic subfoveal choroidal neovascularization (CNV).
Prospective interventional case series. Five consecutive patients (5 eyes) with idiopathic subfoveal CNV were treated with 2.50 mg of intravitreal bevacizumab and followed. Safety, clinical appearance, best corrected visual acuity (BCVA), optical coherence tomography (OCT), fluorescein angiography (FA) and multifocal electroretinogram (m–ERG) were recorded
Mean age was 47.6 years (range 36 to 56 years), mean follow–up was 3 months. Reinjection was not necessary. There were no serious ocular or systemic adverse events. Initial BCVA was –0.70 LogMAR and foveal thickness was 262 micron, one month BCVA was – 0.30 and foveal thickness was 196 micron.
Intravitreal bevacizumab is safe, statistically significant differences was demonstrated between baseline BCVA and foveal thickness. Long term follow–up should be done.
This PDF is available to Subscribers Only